IVACC Intervacc AB (publ)

0.0667USD0.6780 SEK · STO+0.89%Mkt Cap: 22.74M USDP/E: —

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against strep…

Key Statistics

Company
Market Cap22.74M USD
Enterprise Value12.65M USD
Revenue (TTM)1.82M USD
Gross Profit-1.13M USD
Net Income (TTM)-7.95M USD
Revenue/Share0.0053 USD
Last Price0.0667 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees16
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009607252
Valuation
P/E (Trailing)—
P/E (Forward)-0.83
PEG—
EV/EBITDA-1.47
EV/Revenue6.97
P/S12.53
P/B1.10
EPS (TTM)-0.03 USD
EPS (Forward)-0.08 USD
52W Range
0.056312% of range0.1439
52W High0.1439 USD
52W Low0.0563 USD
Profitability
Gross Margin-57.18%
Oper. Margin-576.81%
EBITDA Margin0.00%
Profit Margin-402.32%
ROE-29.40%
ROA-27.45%
ROIC-73.17%
ROCE-30.37%
Growth
Revenue Growth12.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.48M USD
CapEx (TTM)111.42K USD
FCF Margin-194.98%
FCF Yield-15.56%
Net Debt-9.71M USD
Net Debt/EBITDA1.13
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio4.27
Quick Ratio3.89
Book Value/Sh0.06 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.1526 USD
Upside (mean)+128.6%
Target Range0.1476 USD – 0.1575 USD
0.1476+128.6% to mean0.1575
# Analysts2
Ownership
Shares Out.340.81M
Float194.32M
Insiders17.98%
Institutions29.79%
Technical
SMA 500.0860 (-22.4%)
SMA 2000.1013 (-34.1%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)558.91K
Avg Vol (10d)829.93K
Technical Indicators
RSI (14)35.3
MACD-0.0530
MACD Signal-0.0468
MACD Hist.-0.0062
BB Upper0.0877 USD
BB Middle0.0756 USD
BB Lower0.0636 USD
BB Width31.78%
ATR (14)0.0058 USD
Vol Ratio (20d)0.67x

About Intervacc (STO: IVACC)

›

Intervacc (STO: IVACC) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.

The shares were at 0.6780 SEK on 19 November 2026, down 27.1% over 52 weeks. Its 52-week range is 0.5720 SEK to 1.462 SEK: the price is 53.6% below the high and 18.5% above the low.

Its market capitalisation is 231.07M SEK.

Intervacc reports return on equity of -29.4% and revenue up 12.1% year over year.

It holds more cash than debt, a net cash position of 98.69M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 1.550 SEK is 128.6% above the current price. The next earnings report is expected on 17 February 2027.